How to Get Addyi in Maine: Telehealth, Prescriptions, and Pharmacy Guide

What Is Addyi and Why Does Access Vary by State?

Flibanserin 100 mg, sold as Addyi, is the only FDA-approved non-hormonal oral treatment for generalized acquired HSDD in premenopausal women. FDA approval details are on the Addyi prescribing label. Access varies because the drug carries a REMS (Risk Evaluation and Mitigation Strategy) requirement tied to the alcohol interaction warning, and individual state telehealth laws govern whether an out-of-state clinician may write the prescription.

HSDD is defined as persistently low sexual desire that causes marked distress or interpersonal difficulty, with no adequate explanation from a co-existing medical or psychiatric condition. The DSM-5 diagnostic criteria are summarized in the NIH StatPearls database. Prevalence data from the National Health and Social Life Survey estimated that approximately 9.5% of U.S. women aged 18 to 44 experience low sexual desire with personal distress, the two-part threshold required for an HSDD diagnosis. See the NCBI archive of that dataset.

Maine operates under a telehealth-permissive framework. A clinician holding an active Maine medical, nurse practitioner, or physician assistant license may prescribe a Schedule IV controlled substance (flibanserin is not scheduled, making this point moot for Addyi specifically) or any prescription drug to a Maine patient following a synchronous audio-video visit that meets the standard of care. Maine's telehealth statute, 22 M.R.S. § 3173-D, is summarized by Maine DHHS.

The BEGONIA Trial: What the Evidence Actually Shows

The BEGONIA trial (N=1,378 premenopausal women with acquired generalized HSDD) is the most cited key Phase 3 study supporting Addyi's approval. Published in the Journal of Sexual Medicine in 2014, it found that flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks. The primary endpoint showed a mean increase of approximately 0.5 additional SSEs per 28 days versus placebo (P<0.001). Secondary endpoints including the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Revised also improved significantly. The full FSFI validation study is indexed on PubMed.

A pooled analysis of three Phase 3 trials (combined N=2,400) confirmed the SSE benefit and showed that dizziness, somnolence, nausea, and fatigue were the most common adverse events, each occurring in 8-11% of participants on active drug versus 2-4% on placebo. The pooled safety data appear in a 2016 Obstetrics and Gynecology review. Discontinuation due to adverse events was 13% in the flibanserin group versus 6% in the placebo group across the pooled dataset.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that flibanserin produces "a modest but statistically significant improvement in desire and distress scores" and recommends it as a second-line pharmacological option after ruling out reversible causes such as relationship conflict, depression, low testosterone (in postmenopausal women), and medication side effects. Access the Endocrine Society guideline here.

Who Can Prescribe Addyi in Maine?

Any Maine-licensed prescriber with authority to write prescription medications may prescribe flibanserin. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) operating within their scope of practice under Maine law. Maine Board of Nursing scope-of-practice rules for NPs are published here.

NPs with full practice authority in Maine, granted under 32 M.R.S. § 2102, do not require physician oversight to prescribe Addyi. PAs must prescribe within a delegated prescribing agreement, but that agreement does not require separate approval for any specific non-controlled drug. Flibanserin is not a controlled substance at the federal level. The FDA's drug scheduling reference confirms this.

Telehealth prescribers serving Maine patients must hold an active Maine license. An existing relationship with the patient, established via a prior synchronous visit, satisfies Maine's prescribing standard. A text-only or asynchronous visit alone is insufficient for an initial Addyi prescription under current Maine telehealth guidance. CMS telehealth prescribing standards referenced by Maine Medicaid are available at CMS.gov.

Step-by-Step: Getting an Addyi Prescription in Maine

Getting Addyi involves four stages: clinical assessment, safety screening, prescription issuance, and pharmacy dispensing.

Stage 1: Clinical Assessment (30-45 minutes)

The clinician uses a validated tool such as the FSFI or the Sexual Interest and Desire Inventory-Female (SIDI-F) to confirm HSDD. The SIDI-F validation is indexed on PubMed. The visit must rule out depression (PHQ-9 screen), relationship distress, hormonal causes (thyroid dysfunction, hyperprolactinemia), and medication-induced desire loss (common with SSRIs, OCPs, and antihypertensives). An NCBI review of medication-induced sexual dysfunction covers the differential.

Stage 2: Safety Screening

Three safety checks are required before a prescription is issued:

1. Alcohol use: The REMS program requires clinicians to counsel patients that drinking alcohol within two hours before taking flibanserin substantially raises hypotension and syncope risk. The FDA REMS document is at accessdata.fda.gov. Patients with an alcohol use disorder should not receive flibanserin.

2. Liver function: Flibanserin is contraindicated in moderate-to-severe hepatic impairment. A baseline ALT/AST panel is recommended. The pharmacokinetic data supporting this contraindication appear in the FDA label.

3. Drug interactions: CYP3A4 inhibitors (including fluconazole, ketoconazole, several HIV antiretrovirals, and grapefruit juice) significantly increase flibanserin plasma concentration and are contraindicated. The drug interaction list is reviewed in a 2016 Clinical Pharmacology and Biopharmaceutics paper indexed at PubMed.

Stage 3: Prescription Issuance

The clinician issues a standard written or electronic prescription. No special DEA number is required. The prescriber must have completed the Addyi REMS prescriber certification, a one-time online training. REMS enrollment is managed through the FDA REMS portal.

Stage 4: Pharmacy Dispensing

The patient takes the prescription to any retail pharmacy in Maine with flibanserin in stock, or uses a mail-order pharmacy. Pharmacists dispensing Addyi must also be REMS-certified. The pharmacy REMS requirements are outlined at accessdata.fda.gov.

Telehealth Providers in Maine Prescribing Addyi

Several telehealth platforms operate with Maine-licensed clinicians who prescribe flibanserin. HealthRX provides synchronous telehealth visits with clinicians credentialed in Maine, following the full BEGONIA-aligned HSDD assessment protocol. The American Telemedicine Association publishes standards for telehealth prescribing. Visits typically run 30 to 45 minutes and are conducted via HIPAA-compliant video.

After the visit, prescriptions are sent electronically to the patient's preferred Maine pharmacy or to a contracted mail-order pharmacy. Maine's telehealth parity law requires insurers to cover telehealth services at parity with in-person visits.

Patients who already see a gynecologist, FNP, or internist in Maine can also request an Addyi evaluation at their next appointment. The clinical workflow is the same whether the visit is in-person or via telehealth.

The HealthRX clinical team uses a structured four-question HSDD screen during the intake visit: (1) Has your desire for sex decreased compared to when it was at its personal best? (2) Does the decrease cause you personal distress? (3) Has the change persisted for at least six months? (4) Is there an identifiable situational or relationship explanation? A "yes" to questions 1, 2, and 3, with "no" to question 4, satisfies the minimum threshold for proceeding to a full FSFI assessment and considering flibanserin.

Labs Needed Before Addyi in Maine

Labs are targeted rather than exhaustive. A baseline liver panel (ALT, AST, alkaline phosphatase, total bilirubin) is required to rule out moderate-to-severe hepatic impairment, the only absolute lab-based contraindication. The hepatic impairment pharmacokinetics are detailed in the FDA prescribing label.

Thyroid-stimulating hormone (TSH) is ordered when hypothyroidism has not been recently excluded, because untreated hypothyroidism is a reversible cause of low libido that must be addressed before attributing the symptom to primary HSDD. An NIH review of thyroid dysfunction and sexual function supports this practice. Total testosterone and free testosterone (by equilibrium dialysis) are checked in perimenopausal patients to rule out androgen deficiency contributing to desire loss. The Endocrine Society's 2014 testosterone therapy guideline addresses this workup.

A prolactin level is added when galactorrhea, amenorrhea, or visual-field symptoms are present. Routine CBC, CMP, or lipid panels are not required for the Addyi workup specifically.

Most patients can have labs drawn through any Maine-licensed lab, including LabCorp and Quest locations operating statewide. Results are typically returned within 24 to 72 hours. Quest Diagnostics Maine locations are registered with CLIA under CMS oversight.

Addyi Pharmacy Access in Maine: Retail, Mail-Order, and 503A Compounding

Retail pharmacies: Major chains including CVS, Walgreens, and Hannaford Pharmacy locations across Maine stock or can order flibanserin 100 mg. Because Addyi requires pharmacist REMS certification, patients should call ahead to confirm the pharmacist on duty is REMS-certified before making the trip.

Mail-order pharmacies: REMS-certified mail-order pharmacies ship to Maine. Shipping to Maine is legally permitted for prescription non-controlled drugs. Standard shipping takes 3 to 5 business days after the prescription is verified. Expedited shipping reduces that to 1 to 2 business days.

503A compounding pharmacies: Licensed 503A compounding pharmacies in Maine may prepare flibanserin in non-standard forms (for example, a different concentration or a capsule formulation for patients with tablet-swallowing difficulties) when a prescriber documents a valid clinical rationale and the patient has a patient-specific prescription. USP standards governing 503A sterile and non-sterile compounding are referenced by FDA here. Compounded flibanserin is not FDA-approved and lacks the REMS branding requirements of commercial Addyi, but the active ingredient is the same molecule. Patients should confirm that their chosen 503A pharmacy is licensed by the Maine Board of Pharmacy. Maine Board of Pharmacy licensing lookup is maintained by the Maine OPLR.

Brand Addyi's list price is approximately $800 to $900 per 30-tablet supply. Sprout Pharmaceuticals offers a savings card that may reduce out-of-pocket cost to roughly $99 per month for commercially insured patients. Generic flibanserin is available and typically priced significantly lower.

Maine Medicaid Prior Authorization for Addyi

Maine Medicaid (MaineCare) covers flibanserin for premenopausal women with HSDD, subject to prior authorization. The PA process requires documentation of four elements:

1. A confirmed HSDD diagnosis using DSM-5 criteria, documented in the medical record.
2. Evidence that reversible causes of low desire have been assessed and either treated or excluded. The APA DSM-5 diagnostic criteria for FSIAD are available via the APA.
3. Documentation that the patient has been counseled on the alcohol interaction and has agreed to abstain from alcohol within two hours of each dose.
4. A copy of the prescriber's REMS certification number.

MaineCare typically processes standard PA requests within 3 to 5 business days. Expedited PA review for urgent clinical need is processed within 24 hours. If a PA is denied, the prescriber may file an appeal citing the BEGONIA trial data and the Endocrine Society guideline. MaineCare pharmacy benefit policies are published at maine.gov.

Patients with commercial insurance should check formulary tier placement. Many commercial plans in Maine cover generic flibanserin at Tier 2 or Tier 3, with PA requirements similar to MaineCare's. The NCQA formulary transparency standards apply to Maine-licensed insurers.

Transferring an Existing Addyi Prescription to Maine

Patients relocating to Maine with an existing flibanserin prescription from another state can transfer it in most cases. Federal law permits one transfer of a non-controlled prescription between pharmacies. Flibanserin is not a federally controlled substance, so transfers follow standard non-controlled drug rules. FDA's prescription transfer guidance is at fda.gov.

The receiving Maine pharmacy must be REMS-certified. Call the Maine pharmacy first to confirm REMS status before initiating the transfer. If the receiving pharmacy is not REMS-certified, the prescriber will need to send a new prescription directly.

Patients who moved to Maine and whose original prescribing clinician is not licensed in Maine will need a new evaluation with a Maine-licensed provider to receive ongoing refills. Telehealth makes this straightforward: a 20-to-30-minute synchronous video visit with a Maine-licensed clinician is sufficient to establish care, review the existing prescription, and issue a Maine-valid renewal. ATA standards for continuity of care in telehealth are at americantelemed.org.

How Long Until You Receive Addyi in Maine?

The total time from first telehealth visit to first dose breaks down as follows: telehealth visit scheduling (same-day to 48 hours depending on platform), lab turnaround if ordered (24 to 72 hours), prescription issuance (same-day as cleared labs), pharmacy processing and dispensing (1 to 2 business days for retail, 3 to 7 for mail-order). Most patients without PA requirements receive their first supply within 3 to 7 business days of their clinical visit. Patients requiring MaineCare PA add 3 to 5 business days to that timeline.

Starting Addyi at 50 mg for the first two weeks is not an FDA-approved titration strategy. The approved dose is 100 mg nightly from day one. The prescribing label confirms this. Response should be assessed at 8 weeks. If no meaningful improvement in SSEs or desire scores is apparent by week 8, the prescriber should reassess the diagnosis and consider discontinuation. The 8-week response assessment guidance comes from the FDA label and is corroborated by the BEGONIA trial timeline.